LARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, will be featured at the ScaleUp 360° Competitive Intelligence in Pharma & Life Science virtual conference. ScaleUp 360° brings together the industries' top decision makers in pharma and life science working on competitive and market intelligence tools and strategies.
San Francisco, CA (April 6, 2021) – BUSINESS WIRE – LARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, will be featured at the ScaleUp 360° Competitive Intelligence in Pharma & Life Science virtual conference. ScaleUp 360° brings together the industries' top decision makers in pharma and life science working on competitive and market intelligence tools and strategies.
LARVOL will use the event to rollout the launch of their proprietary tool for pharma social listening, VIEW. VIEW is the first social listening and sentiment analysis platform focused on Twitter-verified oncologists, researchers, and Digital Opinion Leaders (DOLs). LARVOL’s team of MDs and PhDs collates data from over 25,000 sources and distills the most relevant findings into concise reports that provide real-time insights and time-saving analysis. Access to this curated information will enable pharma CI teams to make informed, up-to-the-minute decisions influencing their oncology drug positioning.
“By now, most pharma CI teams understand that social listening is a must-have piece of their competitive intelligence strategy,” said LARVOL Head of Operations, Sabrina Bellisario. “But implementation remains a grey area. To truly benefit from the wealth of information social listening presents, CI teams need a clearer picture of what success looks like and what tools and strategies can help them get the data they need to bring product to market.”
“There’s a significant void in the market for tools tailored to the social listening needs of pharma,” Bellisario continues. “VIEW answers that need with an intuitive, easy-to-use solution for CI teams looking to cut through the white noise and tap into the immediate news, trending discussions and, more importantly, the sentiment of DOL’s reactions to immediately influence their product development and go-to market strategies.”
For more information visit LARVOL.com.
LARVOL supports the data and intelligence needs of the pharmaceutical and biotech industry with expert curated information. Their products include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases. LARVOL curates data using a proven combination of broad therapeutic-area expertise and proprietary natural language processing technology to keep their customers at the forefront of the industry. The VR-first, remote-always LARVOL team includes MDs, PhDs, and industry professionals around the globe who curate data from over 25,000 sources and distill the most relevant information into concise reports that provide real-time insights and time-saving analysis.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network